SEC Company Response from CYTOKINETICS INC (CYTK) (CIK 0001061983) (CYTK) — Dec 17, 2014
CYTOKINETICS INC (CYTK) (CIK 0001061983)
Date: Dec. 17, 2014 · CIK: 0001061983 · Accession: 0001193125-14-445726
AI Filing Summary & Sentiment
Reasoning
Referenced dates: December 11, 2014
Letter
[Cytokinetics letterhead]
Via EDGAR
December 17, 2014
Securities and Exchange Commission
Attention:
Jim B. Rosenberg
Mary Mast
Frank Wyman
100 F Street, N.E.
Washington, D.C. 20549
Re:
Cytokinetics, Inc.
Form 10-K for Fiscal Year Ended December 31, 2013
Filed March 7, 2014
File No. 0-50633
Ladies and Gentlemen:
On behalf of Cytokinetics, Inc. (the “Company”), this letter is being submitted in response to comments received from the staff (the “Staff”) of the Securities and Exchange Commission by letter dated December 11, 2014, with respect to the Company’s Form 10-K for Fiscal Year Ended December 31, 2013.
Please be advised that the Company currently expects that it will provide its response to the Staff’s comment letter on or before January 9, 2015 and will further advise the Staff if it becomes unable to do so.
Please do not hesitate to contact me at (650) 624-3009 if you have any questions or would like any additional information regarding this matter.
Sincerely,
/s/ Sharon A. Barbari
Show Raw Text
CORRESP 1 filename1.htm CORRESP [Cytokinetics letterhead] Via EDGAR December 17, 2014 Securities and Exchange Commission Attention: Jim B. Rosenberg Mary Mast Frank Wyman 100 F Street, N.E. Washington, D.C. 20549 Re: Cytokinetics, Inc. Form 10-K for Fiscal Year Ended December 31, 2013 Filed March 7, 2014 File No. 0-50633 Ladies and Gentlemen: On behalf of Cytokinetics, Inc. (the “Company”), this letter is being submitted in response to comments received from the staff (the “Staff”) of the Securities and Exchange Commission by letter dated December 11, 2014, with respect to the Company’s Form 10-K for Fiscal Year Ended December 31, 2013. Please be advised that the Company currently expects that it will provide its response to the Staff’s comment letter on or before January 9, 2015 and will further advise the Staff if it becomes unable to do so. Please do not hesitate to contact me at (650) 624-3009 if you have any questions or would like any additional information regarding this matter. Sincerely, /s/ Sharon A. Barbari Sharon A. Barbari Exec. Vice President, Finance & CFO cc: Marjorie Wagman, General Counsel